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a b s t r a c t
HPVs are the causative agents of approximately 5% of all human cancers, with cervical cancer being the
most predominant. To understand the mechanism of action of the viral E6 oncoprotein, we analysed the
effects of E6 upon potential cellular target proteins. One candidate is FHL-2, involved in the regulation of
signal transduction pathways from the multimeric complexes assembled at focal adhesions. We show
that both HPV E6 and E6n can interact with FHL-2 in vitro, but unlike most E6 targets, FHL-2 does not
appear to be an E6 degradation target. Analysis of the patterns of FHL-2 distribution within HPV-positive
tumour-derived cells shows a signiﬁcant alteration in the pattern of FHL-2 localisation when compared
to non-HPV containing cells. This perturbation of FHL-2 distribution is proteasome-dependent and
inhibition of E6 expression restores the normal distribution of FHL-2. These results conﬁrm FHL-2 as a
new interacting partner of the HPV-E6 oncoproteins.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human papilloma viruses (HPV) are responsible for 5% of the
global cancer burden (Ferlay et al., 2014). Persistent HPV infection
is associated with different types of cancer including, but not
limited to, cervical cancer, and a subset of head and neck cancers
in which the HPV genome is frequently found integrated into the
genome of the host cell (zur Hausen, 1996). As a consequence of
this DNA integration event, viral replicative capacity is lost and
there is subsequent constitutive expression of the viral oncopro-
teins E6 and E7. Indeed, many studies have shown that both viral
oncoproteins are essential for the continued proliferation and
development of HPV positive tumours and the derived cell lines
(von Knebel Doeberitz et al., 1992; Butz et al. 1996; Magaldi et al.,
2012), highlighting their importance as potential targets for
therapeutic intervention in HPV-induced malignancies.
Whilst E6 and E7 are continually expressed, alternative splicing
within E6 results in the appearance of small truncated forms of E6,
called E6n (Smotkin and Wettstein, 1986). Several studies have
demonstrated that E6n isoforms function as potential regulators of
full length E6 (Pim and Banks, 1999), although E6n also possesses a
number of E6 independent functions (Filippova et al., 2007; Pim
et al., 2009; Williams et al., 2014). Although E6 and E6n have been
extensively studied, the mechanisms by which they contribute
towards the development of malignancy still remain to be deﬁned.
One means of understanding how viral oncoproteins contribute
towards malignant progression is to identify their respective cellular
interactomes. In one such recent study, the Four and a Half LIM only
protein 2 (FHL-2) was deﬁned as a potential interacting partner of
HPV-18 E6n (Rozenblatt-Rosen et al., 2012). FHL-2 is a multifunctional
protein involved in a wide range of cellular processes, including the
regulation of gene expression, cytoskeletal architecture, cell adhesion,
cell survival, cell mobility and signal transduction (Li et al., 2001;
Johannessen et al., (2006); Mori et al., 2006). This occurs primarily
through the ability of FHL-2 to assemble multi-protein complexes via
its LIM domains, which function as scaffolds to support the assembly
of multimeric protein complexes (Kadrmas and Beckerle, 2004). This
multi-functionality of FHL-2 appears to be dependent uponwhere it is
localised within the cell. For example, cytoplasmic forms of FHL-2
interact with integrins and focal adhesion kinase (Gabriel et al., 2004),
where it is involved in the regulation of signal transduction pathways
originating at focal adhesions. In the nucleus, FHL-2 interacts with a
number of DNA binding factors and can contribute to the control of a
variety of different transcriptional programs, including those regulated
by AP1 and -ß-catenin, and elevated levels of FHL-2 expression
have been associated with increased tumour invasion and metastasis
(Kleiber et al., 2007).
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However the role of FHL-2 in cancer development is contro-
versial since, although it is up regulated in ovarian, skin, colon,
lung and breast cancers, it is down regulated in prostate and
rhabdomyosarcoma (Kleiber et al., 2007). To date there are no
reports on the status of FHL-2 in cervical cancer, although FHL-2 is
highly expressed in normal cervical tissue (Pontén et al., 2008).
Previous studies have shown that FHL-2 was an interacting
partner of HPV-16 E7. As a consequence of this, the co-activator
function of FHL-2 on the AP1-dependent and β-catenin-dependent
promoters was impaired by E7 (Campo-Fernández et al., 2007).
However, considering the recently published proteomic analyses
indicating FHL-2 as a potential interacting partner of HPV-18 E6n
(Rozenblatt-Rosen et al., 2012), we initiated a series of studies to
investigate whether full-length HPV E6 or E6n has any propensity
to modulate FHL-2 function. We present compelling evidence to
suggest that HPV E6 speciﬁcally alters the subcellular distribution
of FHL-2, which occurs in a proteasome-dependent manner.
Results
High risk HPV E6 proteins interact with FHL-2 in Vitro
Previous proteomic analyses indicated that FHL-2 was a speciﬁc
target of HPV-18 E6n (Rozenblatt-Rosen et al., 2012). However
since E6n shares a large amount of sequence homology with the N-
terminus of the full-length HPV E6, we were interested in
comparing the capacity of full-length E6 and E6n to interact with
FHL-2 in vitro. To do this full length E6 protein and E6n from HPV-
16 and HPV-18 were expressed as GST fusion proteins and puriﬁed,
as was the low risk HPV-11 E6 for comparison. FHL-2 was in vitro
transcribed, translated and radiolabeled with 35S-Methionine and
incubated with the different GST-E6 proteins at 4 1C. After several
washes the protein complexes were analysed by SDS-PAGE and
autoradiography. The results in Fig. 1A show a clear interaction
between the different full-length E6 proteins from HPV-16 and
HPV-18 with FHL-2, but somewhat weaker interaction with HPV-
11 E6 and E6n. Since HPV-16 E7 has previously been shown to be
an interacting partner of FHL-2 (Campo-Fernández et al., 2007),
we also compared the relative abilities of E6 and E7 to interact
with FHL-2 in an in vitro pull down assay. As can be seen from
Fig. 1B, both HPV-16 and HPV-18 E6 interact with FHL-2 much
more strongly than HPV-16 E7 under these assay conditions. These
results are in agreement with recent proteomic studies, which also
failed to detect FHL-2 in HPV E7 complexes (White et al., 2012;
Rozenblatt-Rosen et al., 2012).
E6 affects FHL-2 localisation in HeLa cells
Several E6 interacting partners are targeted for proteasome-
mediated degradation by the E6 oncoprotein (Banks et al., 2003;
Beaudenon and Huibregtse, 2008). However we found little
evidence that HPV-16 E6, HPV-18 E6, or the E6n isoforms, could
affect the levels of FHL-2 expression in either in vitro degradation
assays or in transient transfection experiments in vivo (data not
shown). We were therefore interested in determining whether E6
could exert any potential effects on the pattern of FHL-2 expres-
sion in cells expressing endogenous E6. To do this we monitored
the pattern of FHL-2 expression in HeLa cells by immunoﬂuores-
cence following siRNA ablation of the expression of either E6 alone
or E6/E7 in combination; siLuciferase was used as a control. The
results in Fig. 2 show that the levels of FHL-2 expression in HeLa
cells are quite low and conﬁned primarily to the cell periphery.
Following ablation of either E6 or E6/E7 expression, there is a
dramatic increase in nuclear p53 levels as would be expected.
Most interestingly, there is also a concomitant general increase in
the strength of FHL-2 staining, with a marked accumulation of
FHL-2 in ﬁbrous structures within the cytoplasm in many of the
p53-rescued cells. This pattern of FHL-2 distribution is very similar
to what has been reported previously (Müller et al., 2002; Wixler
et al., 2007).
E6 perturbs FHL-2 expression in a proteasome-dependent manner
FHL-2 interacts with integrins in the cytoplasm allowing multi-
protein complex formation and thereby regulating signal trans-
duction (Wixler et al., 2000). FHL-2 has also been demonstrated to
be a key regulator of cell growth, cell fate determination, cell
differentiation, and remodelling of the actin cytoskeleton (Li et al.,
2001; Mori et al., 2006). The above results indicate that loss of E6/
E7 expression triggers a re-distribution in the pattern of FHL-2
expression. To determine whether the proteasome has a role in the
ability of E6 to perturb the pattern of FHL-2 expression, we
repeated the immunoﬂuorescence analysis in the presence of the
proteasome inhibitor Z-Leu-Leu-Leu-Al (CBZ) including C33A, a
HPV negative cell line, and two HPV containing cell lines CaSki
(HPV16) and HeLa (HPV18). As can be seen in Fig. 3A and B,
untreated HeLa and CaSki cells display low levels of expression of
both FHL-2 and p53. However proteasome inhibition results in a
signiﬁcant increase in nuclear p53 and a dramatic increase in the
levels of cytoplasmic ﬁbrous structured FHL-2, both of which are
similar to the results obtained following ablation of E6/E7 expres-
sion. In contrast the HPV negative C33A cells display a low level of
expression of FHL-2 expression and mutant nuclear p53, and CBZ
treatment has no effect on the pattern of p53 or FHL-2 staining
(Fig. 3C). This indicates that E6/E7 can modulate the pattern of
FHL-2 distribution in a manner that is proteasome-dependent.
To determine whether these FHL-2 cytoplasmic structures, which
are restored following proteasome inhibition or E6 removal, are
Fig. 1. FHL-2 interacts speciﬁcally with HPV E6 protein in Vitro and in Vivo. Puriﬁed
GST-E6 (A) and GST-E7 (B) proteins were incubated with in Vitro translated FHL-2
protein at room temperature. After several washes the bound proteins were
analysed by SDS-PAGE and autoradiography. The FHL-2 bound protein is indicated
by the arrows and the lower panel shows the Coomassie stain indicating the GST
protein balance. 20% input is also indicated.
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associated with stress ﬁbres, we repeated the immunoﬂuorescence
analysis by co-staining for FHL-2 and actin stress ﬁbres with
Phalloidin following proteasome inhibition. As can be seen in
Fig. 3D, FHL-2 is again rescued after proteasome inhibition and
shows a signiﬁcant degree of co-localisation with actin stress ﬁbres.
In contrast, the HPV negative cell line C33A did not show any
change in FHL-2 distribution after proteasome inhibition (Fig. 3E)
and actin stress ﬁbre distribution remained unchanged.
Discussion
HPV induced carcinogenesis relies on the continued expression
of E6 and E7 (Yoshinouchi et al., 2003). This, in turn, regulates a
plethora of signal transduction pathways leading to the transfor-
mation and immortalisation of the cell.
The ability of E6 to induce the degradation of its cellular partners
has been proposed to be one of the fundamental mechanisms by
which E6 can contribute towards malignant progression (Howie
et al., 2009). A recent protein-based analysis provided new insights
into the E6 interacting partners (Rozenblatt-Rosen et al., 2012).
Among them, FHL-2 is of particular interest since it regulates signal
transduction by acting as a scaffold protein in an integrin-dependent
manner (Li et al., 2001). In this study we show that high-risk HPV E6
proteins interact with and modulate the localisation of FHL-2.
The interaction of FHL-2 with high-risk E6 proteins was evident
from the in vitro binding assays. Based on the previous studies
(Rozenblatt-Rosen et al., 2012), an interaction between FHL-2 and
HPV-18 E6n was to be expected. Nevertheless, we demonstrated
that such interaction was somewhat stronger with the full-length
forms of the high-risk HPV E6 proteins, although a signiﬁcant
degree of association was obtained with the low risk HPV-11 E6,
suggesting that E6 association with FHL-2 might be important for
the life cycles of diverse HPV types. Despite extensive attempts we
did not detect any signiﬁcant degree of interaction between HPV-
16 E7 and FHL-2 (Campo-Fernández et al., 2007), although at this
stage we cannot exclude that E7 may nonetheless contribute
towards a modulation of FHL-2 activity in vivo. These biochemical
observations are also in agreement with recent proteomic ana-
lyses, which also failed to detect FHL-2 in E7 complexes (White
et al., 2012; Rozenblatt-Rosen et al., 2012).
Many of the interacting partners of the high-risk HPV E6
proteins are directed for degradation via the proteasome. However
this does not seem to be the case with FHL-2, or at least not
directly. Using either in vitro degradation assays or transient
transfection assays we were unable to demonstrate that E6 could
target FHL-2 for degradation. Likewise, no major changes in the
levels of FHL-2 expression in western blotting following E6
ablation or proteasome inhibition in HPV positive tumour derived
cell lines was observed. Nonetheless, in both CaSki and HeLa cells,
Fig. 2. E6 changes the pattern of FHL-2 expression in HeLa cells. HeLa cells were transfected with siRNA luciferase (si luc), siRNA E6/E7 or siRNA E6 and after 72 h
postransfection cells were ﬁxed and stained for FHL-2 and p53. Note that the p53 signal becomes stronger after E6/E7 and E6 ablation and that FHL-2 accumulates in the
cytoplasm, with the appearance of ﬁbrillar structures in many cases.
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Fig. 3. FHL-2 localisation in HPV positive cells is regulated by the proteasome. C33A, Caski and HeLa cells were seeded on coverslips in six well plates and grown for 24 h to allow
attachment. The next day cells were treated with proteasome inhibitor Z-Leu-Leu-Leu-Al (CBZ) (Sigma) for 3 h prior to ﬁxing as indicated (þ). Then cells were stained for FHL-2 and
p53, with HeLa cells in Panel A, CasKi cells in Panel B and C33A cells in Panel C. Note the increased nuclear p53 in the HPV-positive CBZ treated cells and the concomitant increase in
cytoplasmic FHL-2. Panel D, HeLa cells and Panel E, C33A cells were seeded on coverslips in six well plates and grown for 24 h to allow attachment. The next day cells were treated with
proteasome inhibitor Z-Leu-Leu-Leu-Al (CBZ) (Sigma) 3hrs prior to ﬁxing and stained for FHL-2 using anti-FHL-2 antibody and actin stress ﬁbres detected using Phalloidin (Molecular
Probes). Note that the CBZ treated HeLa cells show some co-localisation of FHL-2 with stress ﬁbres which is not seen in C33A cells.
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FHL-2 expression was quite weak, and was restricted to the cell
periphery. However upon ablation of E6 or E6/E7 there was a
dramatic accumulation of FHL-2, both in terms of the levels of
signal intensity and its subcellular distribution. Likewise, treatment
of CaSKi and HeLa cells with proteasome inhibitors produced
similar changes in the pattern of FHL-2 expression, an effect that
was not observed in HPV-negative C33A cells. Taken together these
results suggest that E6 has a marked effect upon the distribution of
FHL-2 within cells, and this is proteasome dependent. However, it is
tempting to speculate that the apparent overall increase in FHL-2
levels is actually a consequence of FHL-2 accumulation at a deﬁned
location within the cell or, most likely, one of epitope re-exposure
on FHL-2 following loss of E6, rather than an actual real alteration in
FHL-2 total protein levels. Future studies will be required to
investigate these aspects further.
Finally the use of phalloidin staining following proteasome
inhibition in HPV positive cells, also demonstrated that some of
the sites of FHL-2 accumulation are actin stress ﬁbres, which
contrasts with HPV-negative C33A cells where FHL-2 does not
accumulate in such structures, despite there being very clear stress
ﬁbre structures. This is intriguing since stress ﬁbres are involved in
a large number of signal transduction processes and have essential
roles in cell adhesion, integrin signalling and mechano-
transduction and cell morphogenesis (Tojkander et al., 2012).
These results deﬁne FHL-2 as a novel interacting partner of the
high risk HPV E6 oncoproteins, and indicate that the perturbation
of FHL-2 subcellular distribution and the subsequent disruption of
its normal role as a scaffold protein in diverse cell signalling
pathways might be an important element in HPV-induced tumour-
igenesis but also in the HPV life cycle.
Materials and methods
Cells and transfections
C33A (HPV negative cells), CaSki and HeLa (HPV16 and 18
containing cells) cells were maintained in Dulbecco's modiﬁed
Eagle medium (DMEM) supplemented with 10% foetal bovine
serum (FBS).
Fig. 3. (continued)
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GST-fusion proteins puriﬁcation
GST-fusion proteins production and puriﬁcation were described
previously (Pim et al., 1997).
In vitro translation and In vitro binding assays
1 μg of FHL-2 expressing plasmid was in vitro transcribed and
translated using the TNT T7 Coupled Reticulocyte Lysate Systems
(Promega) employing [35S]-Methionine according to the manufac-
turer´s instructions. For the in vitro binding assays equal amounts
of the different E6 GST-fusion proteins were incubated with
in vitro translated FHL-2 in PBS at room temperature for 90 min.
After extensive washing with 0.2% NP-40/PBS the bound proteins
were analysed by SDS-PAGE and autoradiography. GST-fusion
proteins amount was analysed by Coomassie staining.
Immunoﬂuorescence and cell imaging
72 h after siRNA transfection HeLa cells were ﬁxed in4%paraf-
ormaldehyde in PBS for 20 min and permeabilized with 0.1%
Triton-X100, the cells were then incubated for 2 h at 37 1C with
polyclonal anti-FHL-2 antibody (Sigma Aldrich), monoclonal anti-
p53 (DO1, Santa Cruz Biotechnology) either alone or in combina-
tion, washed extensively with PBS, and incubated with anti-rabbit
or anti-mouse conjugated to rhodamine or ﬂuorescein (Molecular
Probes) at 37 1C. Slides were washed and mounted in Vectashield
mounting medium (Vector Laboratories). CBZ treated HeLa cells
were processed in the same manner 72hrs post siRNA transfection
and were incubated with anti p53 (Santa Cruz), anti-FHL-2 anti-
body (Sigma Aldrich) or Phalloidin (Molecular Probes). Slides were
analysed with a Zeiss LSM 510 confocal microscope with two
lasers giving excitation lines at 480 and 510 nm. The data were
collected with a 60X objective oil immersion lens.
siRNA silencing and fractionation experiments
For the delivery of the siRNA (Dharmacon), 120,000 HeLa cells
were seeded in 6 cm diameter dishes and maintained for 24 h to
allow attachment, then cells were transfected with siRNA against
HPV-18 E6 (5´-CUCUGUGUAUGGAGACACATT) or HPV-18 E6/E7
(50CAUUUACCAGCCCGACGAG) and Luciferase as a control, using
the Lipofectamines RNAiMAX Transfection Reagent (Invitrogen)
according to the manufacturer's instructions. 72 h after silencing,
cells were harvested and protein extracted using the sub-cellular
proteome extraction kit (Calbiochem) according to the manufac-
turer's instructions, protein levels were evaluated by western blot.
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